Comparative Pharmacology

Head-to-head clinical analysis: NESACAINE versus PARACAINE.

Peer-Reviewed Evidence

Differential Analysis

NESACAINE vs PARACAINE

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

NESACAINE

Local Anesthetic

Category C

PARACAINE

Local Anesthetic

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Nesacaine (chloroprocaine) is an ester-type local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses.

Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.

Clinical Dosing

Injectable local anesthetic: 1% or 2% solution, maximum dose 7 mg/kg (not to exceed 500 mg) with epinephrine, 4.5 mg/kg (not to exceed 300 mg) without epinephrine. Administer by infiltration or nerve block; may repeat at 30-minute intervals.

10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.

Direct Interaction

None Documented

Half-Life

Terminal half-life: 40-60 minutes (rapidly metabolized by plasma pseudocholinesterase); clinical context: prolonged with hepatic dysfunction or atypical pseudocholinesterase

Other Significant Interactions

Clinical Note

moderate

Proparacaine + Fluticasone propionate

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."

Clinical Note

moderate

Proparacaine + Clemastine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."

Clinical Note

moderate

Proparacaine + Venlafaxine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."

Clinical Note

moderate